Cyber Resilience Act guidance raises the stakes for connected product suppliers

Tern plc

The latest Cyber Resilience Act guidance makes the direction of travel clear for connected product manufacturers. Security now has to be built in from the start, maintained through the life of the product and backed by clear processes for risk management, vulnerability handling and ongoing support.

Companies can no longer treat security as a box-ticking exercise at launch. They need to show that products can stay secure after deployment, through updates, configuration changes, new integrations and extended use in the field. That raises the bar for execution and increases the importance of scalable security operations.

This is especially relevant in IoT and OT markets, where products often stay in service for years and depend on complex supply chains, third-party software and remote services. In that environment, weak processes create risk over time. Manual controls, fragmented systems and assumptions of trust become harder to defend when regulation expects continuous oversight.

Security decisions have to reflect how products work in the real world, including where they are deployed, what data they process, what systems they connect to and which threats they are likely to face. For businesses operating in connected-device markets, this points to the value of stronger device identity, trusted credentials and secure communications. Without those foundations, it becomes harder to enforce policy, manage updates securely or demonstrate that cyber risks are under control.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

Search